tetano
Editor, Senior Moderator
J Steroid Biochem Mol Biol
. 2020 Jun 11;105719.
doi: 10.1016/j.jsbmb.2020.105719. Online ahead of print.
Vitamin D Receptor Stimulation to Reduce Acute Respiratory Distress Syndrome (ARDS) in Patients With Coronavirus SARS-CoV-2 Infections: Revised Ms SBMB 2020_166
Jose Manuel Quesada-Gomez[SUP] 1 [/SUP], Marta Entrenas Castillo[SUP] 2 [/SUP], Roger Bouillon[SUP] 3 [/SUP]
Affiliations
Abstract
Coronavirus infection is a serious health problem awaiting an effective vaccine and/or antiviral treatment. The major complication of coronavirus disease 2019 (COVID-19), the Acute Respiratory Distress syndrome (ARDS), is due to a variety of mechanisms including cytokine storm, dysregulation of the renin-angiotensin system, neutrophil activation and increased (micro)coagulation. Based on many preclinical studies and observational data in humans, ARDS may be aggravated by vitamin D deficiency and tapered down by activation of the vitamin D receptor. Several randomized clinical trials using either oral vitamin D or oral Calcifediol (25OHD) are ongoing. Based on a pilot study, oral calcifediol may be the most promising approach. These studies are expected to provide guidelines within a few months.
Keywords: 1α, 25(OH)2D or 1α, 25-dihydroxyvitamin D or calcitriol; Acute Respiratory Distress syndrome (ARDS); Calcifediol or 25-hydroxyvitamin D3; Corona virus; Cytokine storm; Hypercoagulability; Lung diseases; Renin-angiotensin system; SARS-CoV-2; Vitamin D, vitamin D3 or cholecalciferol.
. 2020 Jun 11;105719.
doi: 10.1016/j.jsbmb.2020.105719. Online ahead of print.
Vitamin D Receptor Stimulation to Reduce Acute Respiratory Distress Syndrome (ARDS) in Patients With Coronavirus SARS-CoV-2 Infections: Revised Ms SBMB 2020_166
Jose Manuel Quesada-Gomez[SUP] 1 [/SUP], Marta Entrenas Castillo[SUP] 2 [/SUP], Roger Bouillon[SUP] 3 [/SUP]
Affiliations
- PMID: 32535032
- PMCID: PMC7289092
- DOI: 10.1016/j.jsbmb.2020.105719
Abstract
Coronavirus infection is a serious health problem awaiting an effective vaccine and/or antiviral treatment. The major complication of coronavirus disease 2019 (COVID-19), the Acute Respiratory Distress syndrome (ARDS), is due to a variety of mechanisms including cytokine storm, dysregulation of the renin-angiotensin system, neutrophil activation and increased (micro)coagulation. Based on many preclinical studies and observational data in humans, ARDS may be aggravated by vitamin D deficiency and tapered down by activation of the vitamin D receptor. Several randomized clinical trials using either oral vitamin D or oral Calcifediol (25OHD) are ongoing. Based on a pilot study, oral calcifediol may be the most promising approach. These studies are expected to provide guidelines within a few months.
Keywords: 1α, 25(OH)2D or 1α, 25-dihydroxyvitamin D or calcitriol; Acute Respiratory Distress syndrome (ARDS); Calcifediol or 25-hydroxyvitamin D3; Corona virus; Cytokine storm; Hypercoagulability; Lung diseases; Renin-angiotensin system; SARS-CoV-2; Vitamin D, vitamin D3 or cholecalciferol.